These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31358316)

  • 1. Corrigendum to "Role of alum in improving the immunogenicity of biodegradable polymer particle entrapped antigens" [Eur. J. Pharm. Sci., 38, (2009), 18-28].
    Kanchan V; Katare YK; Panda AK
    Eur J Pharm Sci; 2019 Sep; 137():105014. PubMed ID: 31358316
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of alum in improving the immunogenicity of biodegradable polymer particle entrapped antigens.
    Kanchan V; Katare YK; Panda AK
    Eur J Pharm Sci; 2009 Aug; 38(1):18-28. PubMed ID: 19467323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and lower dose requirement of polymer entrapped tetanus toxoid co-administered with alum.
    Katare YK; Panda AK
    Vaccine; 2006 Apr; 24(17):3599-608. PubMed ID: 16513224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum to "Formulation and stabilization of norfloxacin in liposomal preparations" [Eur. J. Pharm. Sci. 91 (2016) 208-215].
    Ahmad I; Arsalan A; Ali SA; Bano R; Munir I; Sabah A
    Eur J Pharm Sci; 2016 Oct; 93():507. PubMed ID: 27659781
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy" [Eur. J. Pharm. Sci. 111 (1 January 2018) 492-502].
    Zheng G; Zhao R; Xu A; Shen Z; Chen X; Shao J
    Eur J Pharm Sci; 2018 Mar; 115():381. PubMed ID: 29395834
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to 'The effects of scopolamina on the survival time and microcirculation of septic shock rats'[Eur J Pharm Sci. 141 (2020)105062].
    Song L; Chu R; Cao Z
    Eur J Pharm Sci; 2022 Aug; 175():106240. PubMed ID: 35732568
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to 'Double-dose cefuroxime concentrations in bone, synovial fluid of the knee joint and subcutaneous adipose tissue-A randomised porcine microdialysis study' [Eur J Pharm Sci. 160 (2021) 105754].
    Jørgensen AR; Hanberg P; Bue M; Thomassen MB; Jørgensen NP; Stilling M
    Eur J Pharm Sci; 2022 May; 172():106142. PubMed ID: 35210127
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance" [Eur. J. Pharm. Sci. 131 (2019) 177-194].
    Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
    Eur J Pharm Sci; 2019 Aug; 136():104960. PubMed ID: 31230886
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility.
    Johnson KC
    J Pharm Sci; 2012 Feb; 101(2):681-9. PubMed ID: 21989679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to "Functional electrospun fibers for the treatment of human skin wounds" [Eur. J. Pharm. Biopharm. 119 (2017) 283-299].
    Wang J; Windbergs M
    Eur J Pharm Biopharm; 2018 Nov; 132():93. PubMed ID: 30314750
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Polyethylenimine nanoparticles as an efficient in vitro siRNA delivery system" [Eur. J. Pharm. Biopharm. 73 (2009) 43-49].
    Nimesh S; Chandra R
    Eur J Pharm Biopharm; 2019 Sep; 142():541. PubMed ID: 31470968
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Guanidinium-grafted polyethylenimine: An efficient transfecting agent for mammalian cells" [Eur. J. Pharm. Biopharm. 68 (2008) 647-655].
    Nimesh S; Chandra R
    Eur J Pharm Biopharm; 2019 Sep; 142():542. PubMed ID: 31470969
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery" [Eur. J. Pharm. Biopharm. 129 (2018) 257-266].
    Salade L; Wauthoz N; Vermeersch M; Amighi K; Goole J
    Eur J Pharm Biopharm; 2018 Oct; 131():151. PubMed ID: 30201099
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model." [Eur. J. Pharm. Biopharm. 94 (2015) 521-531].
    Alibolandi M; Sadeghi F; Abnous K; Atyabi F; Ramezani M; Hadizadeh F
    Eur J Pharm Biopharm; 2019 Sep; 142():540. PubMed ID: 31470967
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Andrographolide-loaded nanoparticles for brain delivery: Formulation, characterisation and in vitro permeability using hCMEC/D3 cell line" [Eur. J. Pharm. Biopharm. 119 (2017) 253-263].
    Guccione C; Oufir M; Piazzini V; Eigenmann DE; Jähne EA; Zabela V; Faleschini MT; Bergonzi MC; Smiesko M; Hamburger M; Bilia AR
    Eur J Pharm Biopharm; 2017 Nov; 120():146. PubMed ID: 28941379
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "An insight of in vitro transport of PEGylated non-ionic surfactant vesicles (NSVs) across the intestinal polarized enterocyte monolayers" [Eur. J. Pharm. Biopharm. 127 (2018) 432-442].
    Primavera R; Palumbo P; Celia C; Cilurzo F; Cinque B; Carata E; Carafa M; Paolino D; Cifone MG; Di Marzio L
    Eur J Pharm Biopharm; 2018 Jul; 128():259. PubMed ID: 29738716
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection" [Eur. J. Pharm. Biopharm. 111 (2017) 33-43].
    Tan Z; Liu W; Liu H; Li C; Zhang Y; Meng X; Tang T; Xi T; Xing Y
    Eur J Pharm Biopharm; 2019 Dec; 145():96-97. PubMed ID: 31735275
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Elucidating the weak protein-protein interaction mechanisms behind the liquid-liquid phase separation of a mAb solution by different types of additives" [Eur. J. Pharm. Biopharm. 120 (2017) 1-8].
    Wu G; Wang S; Tian Z; Zhang N; Sheng H; Dai W; Qian F
    Eur J Pharm Biopharm; 2018 Apr; 125():182. PubMed ID: 29428216
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Anticancer activity of galactoxyloglucan polysaccharide-conjugated doxorubicin nanoparticles: Mechanistic insights and interactome analysis" [Eur. J. Pharm. Biopharm. 93 (2015) 183-195].
    Joseph MM; Aravind SR; George SK; Pillai RK; Mini S; Sreelekha TT
    Eur J Pharm Biopharm; 2021 Apr; 161():1-3. PubMed ID: 33722352
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Mimicking brain tissue binding in an in vitro model of the blood-brain barrier illustrates differences between in vitro and in vivo methods for assessing the rate of brain penetration" [Eur. J. Pharm. Biopharm. 127 (2018) 453-461].
    Heymans M; Sevin E; Gosselet F; Lundquist S; Culot M
    Eur J Pharm Biopharm; 2018 Dec; 133():200-202. PubMed ID: 30458954
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.